Research Article Details

Article ID: A25047
PMID: 22215946
Source: World J Gastroenterol
Title: IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice.
Abstract: AIM: To investigate the anti-fibrosis effect of I&#954;B kinase-beta inhibitor (IKK2 inhibitor IMD0354) in liver fibrosis. METHODS: Twenty male C57BL6 mice were divided into four groups. Five high-fat fed mice were injected with lipopolysaccharide (LPS, 10 mg/kg) intraperitoneally and five high-fat fed mice were without LPS injection to build models of liver injury, and the intervention group (five mice) was injected intraperitoneally with IKK2 inhibitor (IMD 30 mg/kg for 14 d), while the remaining five mice received a normal diet as controls. Hepatic function, pathological evaluation and liver interleukin-6 (IL-6) expression were examined. Western blotting and real-time polymerase chain reaction were used to detect the expressions of nuclear factor-&#954;B (NF-&#954;B), alpha-smooth muscle actin (&#945;-SMA), tumor growth factor-beta1 (TGF-&#946;1), tumor necrosis factor-alpha (TNF-&#945;), typeIand type III collagen proteins and mRNA. RESULTS: A mouse model of liver injury was successfully established, and IMD decreased nuclear translocation of NF-&#954;B p65 in liver cells. In the IMD-treated group, the levels of alanine aminotransferase (103 &#177; 9.77 &#956;/L vs 62.4 &#177; 7.90 &#956;/L, P < 0.05) and aminotransferase (295.8 &#177; 38.56 &#956;/L vs 212 &#177; 25.10 &#956;/L, P < 0.05) were significantly decreased when compared with the model groups. The histological changes were significantly ameliorated. After treatment, the expressions of IL-6 (681 &#177; 45.96 vs 77 &#177; 7.79, P < 0.05), TGF-&#946;1 (Western blotting 5.65% &#177; 0.017% vs 2.73% &#177; 0.005%, P < 0.05), TNF-&#945; (11.58% &#177; 0.0063% vs 8.86% &#177; 0.0050%, P < 0.05), typeIcollagen (4.49% &#177; 0.014% vs 1.90% &#177; 0.0006%, P < 0.05) and type III collagen (3.46% &#177; 0.008% vs 2.29% &#177; 0.0035%, P < 0.05) as well as &#945;-SMA (6.19 &#177; 0.0036 &#956;/L vs 2.16 &#177; 0.0023 &#956;/L, P < 0.05) protein and mRNA were downregulated in the IMD group compared to the fibrosis control groups (P < 0.05). CONCLUSION: IKK2 inhibitor IMD markedly improved non-alcoholic fatty liver disease in mice by lowering NF-&#954;B activation, which could become a remedial target for liver fibrosis.
DOI: 10.3748/wjg.v17.i47.5203